Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies9
  • 7D1.8%
  • 3M-2.0%
  • 1Y34.8%
  • YTD3.8%

Last week, the Pharma industry hasn't moved much but Sandoz Group is up 3.3% in that time. The past year has been better, since the industry has gained 37% in that time. Earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026CHF 556.6bCHF 121.0bCHF 25.1b39.8x22.2x4.6x
Fri, 13 Mar 2026CHF 552.3bCHF 121.3bCHF 25.2b37.1x22x4.6x
Sun, 08 Feb 2026CHF 581.7bCHF 119.7bCHF 24.3b37.1x23.9x4.9x
Tue, 06 Jan 2026CHF 555.7bCHF 120.9bCHF 21.5b35.4x25.9x4.6x
Thu, 04 Dec 2025CHF 544.3bCHF 121.4bCHF 21.6b34.2x25.2x4.5x
Sat, 01 Nov 2025CHF 476.7bCHF 121.7bCHF 21.6b32.4x22x3.9x
Mon, 29 Sep 2025CHF 465.5bCHF 120.2bCHF 20.9b30.6x22.2x3.9x
Wed, 27 Aug 2025CHF 477.7bCHF 120.7bCHF 21.0b30.8x22.7x4x
Fri, 25 Jul 2025CHF 466.8bCHF 118.7bCHF 19.5b27.2x23.9x3.9x
Sun, 22 Jun 2025CHF 444.4bCHF 118.7bCHF 19.2b24.9x23.2x3.7x
Tue, 20 May 2025CHF 432.7bCHF 119.8bCHF 19.4b25x22.3x3.6x
Thu, 17 Apr 2025CHF 411.9bCHF 117.1bCHF 18.4b24.4x22.4x3.5x
Sat, 15 Mar 2025CHF 476.6bCHF 121.8bCHF 19.2b29.4x24.9x3.9x
Mon, 10 Feb 2025CHF 474.0bCHF 123.1bCHF 19.2b22.7x24.6x3.9x
Wed, 08 Jan 2025CHF 439.1bCHF 119.5bCHF 21.4b18.4x20.5x3.7x
Fri, 06 Dec 2024CHF 428.8bCHF 117.7bCHF 21.1b18.4x20.3x3.6x
Sun, 03 Nov 2024CHF 452.2bCHF 117.1bCHF 21.0b19.6x21.5x3.9x
Tue, 01 Oct 2024CHF 454.1bCHF 114.6bCHF 19.3b21.7x23.6x4x
Thu, 29 Aug 2024CHF 472.8bCHF 114.4bCHF 19.2b22.7x24.6x4.1x
Sat, 27 Jul 2024CHF 463.8bCHF 116.6bCHF 19.6b32.9x23.6x4x
Mon, 24 Jun 2024CHF 432.4bCHF 116.2bCHF 19.7b33.9x21.9x3.7x
Wed, 22 May 2024CHF 417.2bCHF 113.4bCHF 20.0b41.1x20.9x3.7x
Fri, 19 Apr 2024CHF 393.9bCHF 112.6bCHF 19.5b35.4x20.2x3.5x
Sun, 17 Mar 2024CHF 389.3bCHF 110.9bCHF 19.2b37.3x20.2x3.5x
Tue, 13 Feb 2024CHF 378.1bCHF 110.1bCHF 19.6b23.9x19.3x3.4x
Thu, 11 Jan 2024CHF 417.2bCHF 119.3bCHF 18.6b27.1x22.4x3.5x
Sat, 09 Dec 2023CHF 401.6bCHF 121.2bCHF 18.9b24.2x21.2x3.3x
Mon, 06 Nov 2023CHF 384.3bCHF 122.4bCHF 19.1b23.4x20.2x3.1x
Wed, 04 Oct 2023CHF 404.5bCHF 113.7bCHF 18.2b44.7x22.2x3.6x
Fri, 01 Sep 2023CHF 405.8bCHF 112.0bCHF 17.9b48.1x22.6x3.6x
Sun, 30 Jul 2023CHF 415.6bCHF 114.5bCHF 19.2b48x21.6x3.6x
Tue, 27 Jun 2023CHF 418.2bCHF 115.1bCHF 18.9b36.7x22.2x3.6x
Thu, 25 May 2023CHF 435.1bCHF 115.6bCHF 18.9b39x23x3.8x
Sat, 22 Apr 2023CHF 441.0bCHF 114.6bCHF 18.8b42.9x23.5x3.8x
Price to Earnings Ratio

23.5x


Total Market Cap: CHF 441.0bTotal Earnings: CHF 18.8bTotal Revenue: CHF 114.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.8x is lower than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 10% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market4.04%
Healthcare2.62%
Pharma1.79%
Pharma1.79%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROP Roche HoldingCHF 318.102.2%
+CHF 5.4b		24.5%PE19.6x
SDZ Sandoz GroupCHF 67.707.2%
+CHF 2.0b		102.5%PE41x
GALD Galderma GroupCHF 157.503.0%
+CHF 1.1b		97.6%PE77.1x
NOVN NovartisCHF 120.280.4%
+CHF 915.9m		33.3%PE21x
DESN Dottikon ES HoldingCHF 348.504.7%
+CHF 214.2m		90.0%PE39.8x

Latest News

BIOV
CHF 28.00
BioVersys
7D
5.7%
1Y
-17.6%
ROP
CHF 318.10
Roche Holding
7D
2.2%
1Y
24.5%
NOVN
CHF 120.28
Novartis
7D
0.4%
1Y
33.3%

NOVN: Dermatology And Immunology Pipeline Plus Dividend Will Shape Balanced Outlook

Analysts have slightly reduced their Novartis price target to CHF121.41 from CHF121.50. This change reflects updated assumptions that combine a somewhat lower revenue growth outlook with a modestly higher profit margin and a small adjustment to the future P/E multiple.
GALD
CHF 157.50
Galderma Group
7D
3.0%
1Y
97.6%
COPN
CHF 95.50
Cosmo Pharmaceuticals
7D
11.3%
1Y
97.7%

COPN: Recent Share Placement Will Support Improved Margins And Future Earnings Potential

Analysts have adjusted their price target on Cosmo Pharmaceuticals to CHF 140.45 from CHF 147.89, citing updated views on fair value, revenue growth, profit margins and future P/E assumptions. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares on February 3, 2026 (Key Developments).
NWRN
CHF 16.66
Newron Pharmaceuticals
7D
15.4%
1Y
150.9%

Late Stage Schizophrenia Pipeline And Extended Patents Will Transform Long Term Prospects

Catalysts About Newron Pharmaceuticals Newron Pharmaceuticals is a biopharmaceutical company focused on developing evenamide as an add-on therapy for schizophrenia and related central nervous system disorders. What are the underlying business or industry changes driving this perspective?
SDZ
CHF 67.70
Sandoz Group
7D
7.2%
1Y
102.5%
DESN
CHF 348.50
Dottikon ES Holding
7D
4.7%
1Y
90.0%